PHIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PHIO is not a good buy right now for an impatient investor. The stock is trading into key support (~1.01) with a bearish trend still accelerating (negative MACD expansion and bearish moving-average stack). With no fresh news/catalysts, no proprietary buy signals, and weak fundamentals (no revenue), the near-term odds skew to further downside before any durable bounce. If you already hold it, this setup favors selling/avoiding adding until momentum turns.
Trend/price context (pre-market): 1.01 (-0.98%), near S1=1.012 and just above S2=0.96, meaning any weakness can quickly break support. Momentum: MACD histogram is negative (-0.00451) and expanding lower, which typically signals increasing bearish momentum. RSI: RSI_6 at 29.823 is near oversold, which can enable short bounces, but by itself is not a buy signal when MACD and moving averages remain bearish. Moving averages: Bearish alignment (SMA_200 > SMA_20 > SMA_5) confirms a downtrend across long, mid, and short timeframes. Levels: Pivot 1.096 is the first upside "trend repair" level; resistance at 1.18 then 1.232. Support at ~1.012 then 0.96. Pattern-based forecast: Similar-pattern analysis implies ~70% chance of -2.05% next day and -1.52% next week, with a potential +3.26% next month (i.e., short-term pressure first).
Intellectia Proprietary Trading Signals
RSI near oversold could spark a short, technical bounce if 0.96–1.01 support holds.
Net loss improved YoY in the latest reported quarter (2025/Q3), which can sometimes help sentiment at the margin.
Next-month pattern signal shows a possible rebound (+3.26%), but it’s preceded by weak near-term probabilities.
Fundamentals remain weak for momentum buyers: latest quarter still shows no revenue and a meaningful loss.
Latest quarter: 2025/Q3. Revenue remained 0 (0.00% YoY). Net income improved to -$2.392M (56.96% improvement YoY), but EPS fell to -0.44 (down 71.43% YoY), indicating per-share profitability worsened despite the headline improvement in net loss. Overall: still a pre-revenue/loss-making profile with no visible growth inflection in sales.
No analyst rating or price target change data was provided, so there is no clear Wall Street "pro vs con" consensus to lean on. With the current dataset, the decision is driven primarily by bearish technicals, lack of catalysts, and weak (zero-revenue) financial trends. Politicians/influential trading: No recent congress trading data available (last 90 days).
